Tech Company Financing Transactions
ATB Therapeutics Funding Round
On 11/18/2024, ATB Therapeutics received $57 million in Series A investment from EQT Life Sciences, MRL Ventures and Sambrinvest.
Transaction Overview
Company Name
Announced On
11/18/2024
Transaction Type
Venture Equity
Amount
$57,000,000
Round
Series A
Investors
EQT Life Sciences (Lead Investor)
MRL Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand and enhance the ATBioFarm platform, as well as to accelerate development of its weaponized antibodies for oncology and immunology applications.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Novalis Science Park, Rue de la Science, 8
Aye, 6900
Belgium
Aye, 6900
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Developing an Innovative Antibody Payload Technology for hard-to-treat cancer and autoimmune disease atbtherapeutics is a pioneering biopharmaceutical company building a pipeline of weaponized antibodies. Those novel therapeutic formats can only be achieved using our proprietary plant-based atbiofarm technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Mark Throsby
Chief Executive Officer
Bertrand Magy
Chief Operating Officer
Max Houry
VP - Bus. Development
Philippe Vandeput
Browse more venture capital transactions:
Prev: 11/17/2024: Factiverse venture capital transaction
Next: 11/18/2024: IonKraft venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs